PropertyValue
?:definition
  • An orally bioavailable inhibitor of mutated mitochondrial enzyme isocitrate dehydrogenase type 2 (IDH2; IDH-2), with potential antineoplastic activity. Upon oral administration, IDH2 mutant inhibitor TQB3455 specifically inhibits mutated IDH2, thereby inhibiting the formation of the oncometabolite 2-hydroxyglutarate (2HG) from alpha-ketoglutarate (a-KG). This prevents 2HG-mediated signaling and leads to both an induction of cellular differentiation and an inhibition of cellular proliferation in tumor cells expressing mutated IDH2. IDH2 is mutated in a variety of cancers, and mutated IDH2 initiate and drive cancer growth by catalyzing the formation of 2HG and blocking cell differentiation.
?:hasCUIAnnotation
?:hasGeneratedBy
?:type

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/C5447424_NCI>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/C5447424_NCI>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all